Drugs / Liberase
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT03514537 Background | Mar 2018 → Mar 2027 | FRAXD syndrome, neurodegenerative disease, premature aging syndrome | Healeon Medical Inc | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liberase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03514537 ↗ |
| Known as | Liberase TM | “Liberase TM for use to enzymatically isolate cellular stromal vascular fraction” NCT03514537 ↗ |
| Modality | Protein / enzyme biologic | “sterile Liberase enzyme” NCT03514537 ↗ |